Predictors of long-term survival in lung cancer patients (p) included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel (D) and carboplatin (Cb) plus induction (I) or consolidation (C) chemotherapy (CT) with docetaxel and gemcitabine (G)

Abstract

Listen

Translate article

7574 Background: There is little information about prognostic variables associated with long term survival in stage III NSCLC p treated with concomitant chemoradiotherapy. Methods: Unresectable stage III p with IK ≥ 70, forced expiratory volume in 1 second (FEV1) of ≥ 1L and weight loss < 5% were initially randomized to sequential treatment (arm A), concurrent CT/TRT followed by consolidation CT (arm B) or induction CT followed by CT/TRT (arm C). Based on RTOG 9410 results, arm A was closed and the study continues with two concomitant arms (B, C). All p receive 2 cycles of D 40 mg/m2 d1, 8 plus G 1,200 mg/m2 d1, 8 as I or C therapy. Concomitant treatment includes D 20 mg/m2 and Cb AUC 2 weekly plus 60 Gy TRT. In order to identify factors that affected survival duration an univariate analysis and a Cox proportional hazards regression were performed including the following variables: age (< 70 or > 70), sex, ECOG (0 vs 1), FEV1 (>2 L vs 1–2 L), stage III (A vs B), N disease (N0 vs N1–2 vs N3), Hb level (≥12 gr/dl vs < 12 gr/dl), RT treatment completed (yes vs no), I or C plus concomitant treatment completed (yes vs no) and prolonged RT delay (≥ 7 days vs > 7 d). Results: From May 01 to Jun 06, 151 p were included (A: 19, B: 66, C: 66). Efficacy and survival data were already presented. With a median follow-up of 23 months (m), no statistically significant differences in terms of MST (13.7 m [B] and 14.6 m [C]) or 4-years survival (27% [B] and 34% [C]) were found. In the Cox regression analysis only RT treatment completed (p < 0.0001) and I or C plus concomitant treatment completed (p < 0.0001) were associated with improved survival. Conclusions: Based in this retrospective analysis neither age, sex, ECOG nor clinical parameters are good predictors for OS in p candidate to concomitant treatment whereas finishing the treatment is needed for achieve long term results. No significant financial relationships to disclose.